Construction method and application of tetracycline repressor protein stable expression cell strain
By constructing a stable expression system of tetracycline repressor protein (TetR), the poor stability of cell lines and the quality of transfection reagents in the prior art were solved, and the stable site-directed insertion and efficient expression of the TetR gene were achieved, which was suitable for gene function research and biological product production .
Patent Information
- Application Number
- CN202310600674.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-25
- Publication Date
- 2024-11-26
AI Technical Summary
The existing tetracycline (Tet) regulatory gene expression system has poor stability in cell lines and is highly randomly inserted, which cannot meet the production needs, and the quality of the transfection reagent is difficult to guarantee.
A stable expression system of tetracycline repressor protein (TetR) was constructed. By inserting the nucleotide sequence encoding TetR into the cloning vector, combining the site-directed cleavage sequence, and using PEI pro transfection reagent, the stable site-directed knock-in and efficient expression of the TetR gene were achieved.
Cell lines that stably express TetR were obtained, ensuring site-directed insertion and efficient expression of genes, suitable for gene function research and biological product production, and the stability and quality of cell lines were improved through bleomycin screening and monoclonal screening.
Smart Images

Figure HDA0004248952670000011 
Figure HDA0004248952670000012 
Figure HDA0004248952670000021
Abstract
Description
Technical Field
[0001] The present disclosure relates to the field of biomedicine, and in particular to a construction system for stably expressing tetracycline repressor protein (TetR), a cell line, and a construction method and application thereof. Background Art
[0002] In 1992, Goseen et al. successfully constructed a tetracycline (Tet) eukaryotic gene regulation expression system using prokaryotic gene regulatory elements. At present, this system has been widely used in the study of gene function and gene therapy. The Tet regulatory expression system changes the conformation of regulatory proteins by inducing drugs (such as tetracycline and doxycycline), thereby achieving the purpose of regulating the expression of target proteins. The Tet regulatory gene expression system is based on the Tet resistance operon on the Escherichia coli Tn10 transposon. The Tet repressor protein (TetR) can specifically bind to the Tet operator (Tetoperator, TetO). When there is no inducing drug, TetR will bind to TetO, thereby blocking the expression of downstream drug resistance genes; when there is an inducing drug, the conformation of TetR will change and detach from TetO, allowing the downstream drug resistance genes to be expressed, and the bacteria will acquire drug resistance.
[0003] Taking advantage of the specific binding characteristics of TetR and TetO, various types of Tet regulatory systems have gradually developed. The key components of the tetracycline-induced gene expression system are the tetracycline response element (TRE) and the tetracycline repressor protein (TetR). Because excessive expression of certain target genes or expression at inappropriate times will affect the cell state or the growth and development of the body, and thus affect the experimental results, the tetracycline (Tet) gene expression system can achieve precise regulation of gene expression.
[0004] However, most existing technologies use lentiviral vectors for random insertion, which is highly random, has a low positive rate, and poor cell line stability. In addition, most of them use cationic liposome transfection reagents, which are generally unable to prove their quality and are not suitable for constructing cells for production. Therefore, there is an urgent need for systems or cells that can stably express TetR. Summary of the invention
[0005] The present invention constructs the tetracycline repressor protein TetR gene into 293 cells to obtain a 293 cell line that can stably express tetR. When a virus or vector carrying an exogenous gene of a tetracycline response element (TRE) is propagated on this cell line, the exogenous gene will be inhibited from being expressed, and the cell function and growth state can be maintained.
[0006] A first aspect of the present disclosure provides a construction system for expressing a tetracycline repressor protein, wherein the construction system comprises a nucleotide sequence encoding the tetracycline repressor protein.
[0007] In some embodiments, the nucleotide sequence encoding the tetracycline repressor protein is as shown in SEQ ID NO: 1, or has one or more nucleotide substitutions, deletions or insertions compared with the nucleotide sequence shown in SEQ ID NO: 1.
[0008] In some embodiments, the nucleotide sequence encoding the tetracycline repressor protein is inserted into a cloning vector to obtain a tetracycline repressor protein expression vector.
[0009] In some embodiments, the cloning vector is selected from, but not limited to, at least one of pMD18T, pUC18, pMD19T, pbs-sk or pGEM-T, preferably pMD18T.
[0010] In some embodiments, the construction system further comprises a site-directed cleavage sequence.
[0011] In some embodiments, the site-directed cleavage sequence is as shown in SEQ ID NO: 2, or has one or more nucleotide substitutions, deletions or insertions compared to the sequence shown in SEQ ID NO: 2.
[0012] In some embodiments, the site-directed cleavage sequence is inserted into a donor plasmid.
[0013] In some embodiments, the donor plasmid is selected from pLentiCRISPRv2.
[0014] The construction system provided by the present disclosure can ensure that the target gene (i.e., the control gene encoding TetR) is stably knocked into the host cell at a specific site.
[0015] A second aspect of the present disclosure provides a cell line obtained using the construction system described in the first aspect.
[0016] In some embodiments, the cell line is a human cell; preferably, the human cell is a HEK293 cell.
[0017] In some embodiments, the cell line is a tetracycline repressor protein stably expressing cell line, which was preserved in Guangdong Microbiological Culture Collection Center on March 13, 2023, with the taxonomic name of human embryonic kidney cell Trex293-LXL06, the preservation number is GDMCC No: 63272, and the address of the preservation unit is the Institute of Microbiology, Guangdong Academy of Sciences, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.
[0018] The third aspect of the present disclosure provides a method for constructing a tetracycline repressor protein stably expressing cell line, the method comprising co-transfecting a tetracycline repressor protein expression vector and a donor plasmid in the construction system into cells.
[0019] In some embodiments, the cell is a human cell. In some specific embodiments, the cell is a HEK293 cell.
[0020] In some embodiments, the method comprises the steps of:
[0021] (1) co-transfecting the linearized product of the tetracycline repressor protein expression vector and the donor plasmid into cells;
[0022] (2) using bleomycin to screen the cells obtained in step (1) for resistance, preferably, the concentration of bleomycin is preferably 200-500 μg / ml;
[0023] (3) Obtain a cell line stably expressing tetracycline repressor protein through monoclonal screening.
[0024] In some specific embodiments, the method includes connecting the site-directed cutting sequence to the pLentiCRISPRv2 vector plasmid to obtain a donor plasmid, connecting the nucleotide sequence encoding TetR to the pMD18T vector plasmid to obtain a recombinant expression vector, linearizing p2 with three restriction endonucleases EcoRI, HindIII, and ScaI, and then recovering it by ethanol precipitation. The donor plasmid and the linearized fragment of the recombinant expression vector are co-transfected into 293 cells, and the gene insertion cell strain carrying the TetR control is selected by bleomycin, and the tetracycline repressor protein stable expression cell strain is obtained by monoclonal screening.
[0025] The fourth aspect of the present disclosure provides the use of the construction system, the cell line or the cell line constructed by the method in gene function research, research and production of preventive and therapeutic biological products.
[0026] Compared with the prior art, the cell line constructed by the method disclosed in the present invention is a site-specific insertion with good stability, and uses the transfection reagent PEI pro commonly used in industrial production, has corresponding quality certificates, can ensure the quality of the cell line, and provides a cell line that can be used for large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 The electrophoresis diagram for the identification of the gene level of the TetR control is shown (M is a 2000 bp marker, 02, 04, and 06 are cell line samples, and the positive control is p2).
[0028] Figure 2The electrophoresis diagram shows the identification results of the transcription level of the TetR control (M is a 2000 bp marker, 02, 04, and 06 are cell line samples, the positive control is p2, and the negative control is ddH2O).
[0029] Figure 3 The analysis results of the absolute expression of the TetR control after reverse transcription by Q-PCR are shown (02, 04, and 06 are cell line samples, and 293 is a wild-type 293 cell without target gene knock-in treatment).
[0030] Figure 4 The figure shows the analysis results of the relative expression levels of the TetR control after reverse transcription by Q-PCR (02, 04, and 06 are cell line samples, and 293 is a wild-type 293 cell without target gene knock-in treatment).
[0031] Figure 5 The figure shows the electrophoresis results of the PCR detection of the stability of the TetR control gene (M is a 2000bp marker, P03, P05, P07 and P10 are the 3rd, 5th, 7th and 10th generation cell samples during 10 consecutive passages of the cell line, and the positive control is p2). DETAILED DESCRIPTION
[0032] In order to make the purpose, technical scheme and advantages of the present disclosure clearer, the present disclosure is further described in detail below in conjunction with the embodiments. The specific embodiments described herein are only used to explain the present disclosure and are not intended to constitute any limitation to the present disclosure. In addition, in the following description, the description of the well-known structures and technologies is omitted to avoid unnecessary confusion of the concepts of the present disclosure. Such structures and technologies are also described in many publications.
[0033] definition
[0034] Unless otherwise defined, all technical and scientific terms used in this disclosure have the same meaning as commonly used in the field to which this disclosure belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.
[0035] Unless the context clearly dictates otherwise, the expressions "a", "an" and "an" as used herein include plural references. For example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth.
[0036] 293 cells are a human renal epithelial cell line with a variety of derivative strains, such as HEK293, 293T / 17, etc. They are all derived from human embryonic kidney cells. They rarely express endogenous receptors required for extracellular ligands and are relatively easy to transfect. They are a very commonly used cell line for expressing exogenous genes in research.
[0037] The Tet-regulated gene expression system is based on the Tet resistance operator on the Escherichia coli Tn10 transposon. The Tet repressor protein (TetR) can specifically bind to the Tet operator (TetO). When there is no inducing drug, TetR will bind to TetO, thereby blocking the expression of downstream resistance genes; when there is an inducing drug, the conformation of TetR will change and detach from TetO, allowing the downstream resistance genes to be expressed, and the bacteria will acquire resistance. The tetracycline repressor protein is a non-human protein. The prokaryotic TetR has high binding specificity with TetO, and there is no similar DNA targeting sequence in mammalian cells. Therefore, the Tet system has high regulatory specificity, and the host gene is not affected, which is suitable for the regulation of various gene expressions in vivo and in vitro.
[0038] Examples and drawings are provided below to help understand the present disclosure. However, it should be understood that these examples and drawings are only used to illustrate the present disclosure and do not constitute any limitation. The actual scope of protection of the present disclosure is set forth in the claims. It should be understood that any modifications and changes can be made without departing from the spirit of the present disclosure.
[0039] Experimental equipment: carbon dioxide incubator (ESCO), biological safety cabinet (ESCO), centrifuge (Kecheng Instrument), electrophoresis instrument (BioRad), gel imaging system (BioRad), cell counter (Count Star), PCR instrument (Hangzhou Boheng).
[0040] Experimental materials: p1 plasmid (commissioned by Beijing Qingke Synthesis), p2 plasmid (commissioned by Shanghai GenScript Synthesis), restriction endonucleases (Thermo): EcoRI, HindIII, ScaI, DMEM (Thermo), calf serum (Zhejiang Tianhang), bleomycin (Thermo), transfection reagent PEIpro (Poly Plus), trypsin (Gibco), DPBS (Shanghai Yuanpei), 2000bp Marker (TAKARA), blood / cell / tissue genomic DNA extraction kit (Tiangen), Fast pure cell / Tisue Total RNA Isolation Kit (Novozyme), ReverTra Ace qPCR RTKit (TOYOBO), 6× Loading Buffer (TAKARA), primers (Sangon), iTaq Universal SYBR Green Supermix (BIO-RAD).
[0041] Main solutions: complete medium (DMEM containing 10% calf serum), screening medium (complete medium containing 300 μg / ml bleomycin), maintenance medium (complete medium containing 100 μg / ml bleomycin), reduced serum medium (Opti-MEM, Gibco).
[0042] Example 1: Cell line construction
[0043] 1. Beijing Qinke Technology Co., Ltd. was commissioned to synthesize the site-directed cutting sequence and construct it into the pLentiCRISPRv2 vector plasmid to obtain plasmid p1 (1 μg / μl).
[0044] Among them, the site-directed cutting sequence: ggggccactagggacaggat (SEQ ID NO: 2)
[0045] 2. Entrust Shanghai GenScript to synthesize the sequence and construct it into the pMD18T vector plasmid to obtain plasmid p2 (1 μg / μl).
[0046] Among them, the TetR control gene sequence (SEQ ID NO: 1) is included:
[0047]
[0048] 3. Linearize p2:
[0049] 200μl enzyme digestion reaction system is as follows:
[0050] ddH2O 140μl
[0051] Green buffer 20μl
[0052] p2 (1μg / μl) 10μl
[0053] EcoRI / HindIII / ScaI 10μl each
[0054] Incubate in a water bath at 37°C for 1 h.
[0055] After the enzyme digestion was completed, the p2 linearized fragment was recovered by ethanol precipitation recovery method, and the content was 220 ng / μl detected by micro-ultraviolet spectrophotometer.
[0056] 4. Cell plating: HEK293 (P45) was plated in a six-well plate, 6E+05 cells / well, 4 wells in total, and DMEM complete medium containing 10% calf serum (Zhejiang Tianhang) was used. The cells were cultured at 37°C, 5% CO2 for 24 h, and the confluence was 60%-70% at the time of transfection.
[0057] 5. Transfection:
[0058] (1) Take 13.5 μl of the p2 linearized fragment, 3 μl of the P1 plasmid, and 150 μl of Opti-MEM and mix them to make solution A;
[0059] (2) Take 12 μl of transfection reagent PEI pro and 150 μl of Opti-MEM and mix them evenly to make solution B;
[0060] (3) Mix all of Solution A and Solution B and let stand at room temperature for 15 min to obtain Solution C;
[0061] (4) Add all of Solution C to 3 ml of Opti-MEM and mix to obtain Solution D.
[0062] (5) Use a 1000 μl pipette to discard the culture medium in the six-well plate, add 1.1 ml of D solution to 3 wells, and add 1.1 ml of Opti-MEM to 1 well as a control. After incubation at 37°C, 5% CO2 for 4 h, replace the solution in 4 wells of the six-well plate with complete culture medium and culture at 37°C, 5% CO2 until the confluence reaches more than 70%.
[0063] 6. Expand the culture: transfer all the cell suspensions after digestion in the 3 wells treated with transfection to a T75 culture flask and culture at 37°C, 5% CO2 until the confluence reaches more than 80%.
[0064] 7. Drug screening: Digest the cells in the T75 bottle and plate them in a six-well plate at 1E+06 cells / well, for a total of 6 wells. Culture at 37°C, 5% CO2 until the confluence reaches more than 80%. Replace the culture medium with screening medium and culture at 37°C, 5% CO2 for 7 days, changing the medium every day. After 7 days, replace the maintenance medium and continue to culture at 37°C, 5% CO2 for 14 days. Cell clusters can be observed. Digest the cell clusters and plate them in a 12-well plate, and culture them with maintenance medium for 14 days. After 14 days, transfer to a six-well plate for culture, transfer to a 10cm dish for culture after 5 days, transfer to a 150mm dish for culture after 4 days, and perform monoclonal screening after 2 days of culture.
[0065] 8. Monoclonal screening by limiting dilution method
[0066] (1) After digestion, the cells were resuspended and sampled for cell counting. The counting result was 8.10E+06 cells / ml. 50 μl was added to 19.5 ml of maintenance medium and mixed to dilute the cell suspension to 20,000 cells / ml. 2 ml of the cell suspension was added to 18 ml of maintenance medium and mixed to dilute the cell suspension to 2,000 cells / ml. 2 ml of the cell suspension was added to 18 ml of maintenance medium and mixed to dilute the cell suspension to 200 cells / ml. 2 ml of the cell suspension was added to 18 ml of maintenance medium and mixed to dilute the cell suspension to 200 cells / ml. 5 ml of the cell suspension was plated on 9 wells at 100 μl / well. 6-well plate (2 cells / well), 4 columns (1st to 5th columns); take 10 ml of the remaining cell suspension, add 10 ml of maintenance medium, mix well, i.e. dilute to 10 cells / ml cell suspension, take 5 ml of the cell suspension at 100 μl / well and plate on 96-well plate (1 cell / well), 4 columns (6th to 9th columns); take 10 ml of the remaining cell suspension, add 10 ml of maintenance medium, mix well, i.e. dilute to 5 cells / ml cell suspension, take 5 ml of the cell suspension at 100 μl / well and plate on 96-well plate (0.5 cells / well), 4 columns (10th to 12th columns); culture in a 37°C, 5% CO2 incubator, observe cell growth every 7 days, and replenish 50 μl of fluid every 7 days.
[0067] (2) When the cells grow to a confluence of 80%, they are expanded and cultured. 0.5 cells / well are selected and subcultured from 96-well plates to 48-well plates. Cell growth is observed after culturing in a 37°C, 5% CO2 incubator for 3 to 5 days. When the cells grow to a confluence of 90%, the cells are subcultured to 48-well plates at a ratio of 1:3 and cultured in a 37°C, 5% CO2 incubator. When the cells grow to a confluence of 90%, one well is selected for identification, and the rest are cultured. A total of 28 strains were identified, and 3 of them were selected for identification.
[0068] (3) Identification: Carefully discard the culture supernatant, add 10 μl of ddH2O, and use the liquid after hypotonic cell rupture as a template for PCR.
[0069] PCR primers (PCR product target fragment size is about 1340bp):
[0070] PGK-F:TCTGGAGCATGCGCTTTAGCA(SEQ ID NO:3)
[0071] BGH-R:TAACCATAGAGCCCACCGCATC(SEQ ID NO:4)
[0072] 10 μl of the PCR product was taken for electrophoresis, and the remaining PCR product was entrusted to Aigi Biotechnology for sequencing, with the sequencing primers being PGK-F and BGH-R.
[0073] The electrophoresis results showed that the three cell lines screened could PCR produce a target fragment of about 1340 bp in length ( Figure 1 The sequencing results also showed a match with the original sequence, which indicated that the positive clone cell lines screened were correctly identified at the DNA level.
[0074] (4) Take the cells from the wells identified as positive and grow them to a confluence of 90%, subculture them to a 12-well plate, and culture them in a 37°C, 5% CO2 incubator. When the cells grow to a confluence of 90%, subculture them to a 6-well plate, and culture them in a 37°C, 5% CO2 incubator. When the cells grow to a confluence of 90%, subculture them to a 10 cm dish, and culture them in a 37°C, 5% CO2 incubator. When the cells grow to a confluence of 90%, subculture them to a 150 mm dish, and culture them in a 37°C, 5% CO2 incubator. When the cells grow to a confluence of 90%, some of them are used for freezing, and some are used for identification of transcriptional levels.
[0075] (5) Identification of transcriptional levels: 5E+05 cells were used to extract RNA using an RNA extraction kit (Fast pure cell / Tisue Total RNA Isolation Kit, Norwegian), eluted with 40 μl of deionized water, and 2 μl of the obtained RNA was reverse transcribed using a reverse transcription kit (ReverTra Ace qPCR RTKit, TOYOBO) to obtain cDNA, which was then subjected to PCR identification.
[0076] PCR primers (PCR product target fragment size is about 730bp):
[0077] TetR-F: ggcattctgcacgcttcaaa (SEQ ID NO: 5)
[0078] TetR-R: tggcaactagaaggcacagg (SEQ ID NO:6)
[0079] 10 μl of the PCR product was taken for electrophoresis, and the remaining PCR product was entrusted to Aigi Biotech for sequencing, with the sequencing primers being TetR-F and TetR-R.
[0080] The electrophoresis results showed that the three positive clone cell lines screened were all able to PCR-produce a target fragment of about 730 bp in length after RNA extraction and reverse transcription, followed by PCR identification ( Figure 2 The sequencing results also showed that they matched the original sequence. These results indicate that the three positive clone cell lines screened were correctly identified at the RNA transcription level.
[0081] 9. Cryopreservation:
[0082] (1) Prepare cell freezing solution: calf serum: DMSO = 9:1, mix well and store at 4°C.
[0083] (2) When the cells grow to a confluence of 90%, digest them, count the cells, and freeze them at a volume of 5E+06 cells / ml, 1 ml / vial.
[0084] Example 2: Analysis of target gene expression
[0085] About 1E+05 cells of each of the three correctly identified positive clone cell lines (02, 04 and 06) and 293 cells (negative control) were used for RNA extraction using an RNA extraction kit (Fast pure cell / Tisue Total RNA Isolation Kit, Norwegian). The RNA was eluted with 40 μl of deionized water, and 2 μl of the obtained RNA was reverse transcribed using a reverse transcription kit (ReverTraAce qPCR RTKit, TOYOBO) to obtain cDNA, which was then subjected to Q-PCR and 2 -△△CT The absolute and relative expression levels of the TetR gene were analyzed by the method (plasmid pMD18T-TetR was used as the standard and hGAPDH was used as the internal reference).
[0086] The results of Q-PCR showed that the absolute expression levels of TetR gene in the three positive clone cell lines identified correctly were all high, while the wild-type 293 cells without target gene knock-in treatment had no TetR gene expression ( Figure 3 ); hGAPDH was used as an internal reference for calibration, and 2 -△△CT The relative expression of TetR gene was analyzed by the method, and it was found that the TetR gene of positive clone cell lines 02, 04 and 06 was highly expressed ( Figure 4 ).
[0087] Example 3: Target gene stability detection
[0088] The positive clone cell line (06) that was correctly identified was subcultured. The culture medium was DMEM complete culture medium containing 10% calf serum (Zhejiang Tianhang). The cells were cultured in a 37°C, 5% CO2 incubator for 2 to 5 days before subculture. The culture supernatant was discarded first, and the cells were washed once with DPBS (Shanghai Yuanpei). The cells were then digested with trypsin (Gibco) for 1 to 2 minutes, and then beaten into single cells. The cells were subcultured at a subculture ratio of 1:3 to 1:8, and the subculture was continued for 10 times (P01 to P10). P03, P05, P07 and P10 cell samples were taken, the culture supernatant was carefully aspirated and discarded, 10 μl of ddH2O was added, and PCR was performed using the liquid after hypotonic cell rupture as a template.
[0089] PCR primers (PCR product target fragment size is about 730bp):
[0090] TetR-F: ggcattctgcacgcttcaaa (SEQ ID NO: 5)
[0091] TetR-R: tggcaactagaaggcacagg (SEQ ID NO:6)
[0092] 10 μl of the PCR product was taken for electrophoresis, and the remaining PCR product was entrusted to Aigi Biotech for sequencing, with the sequencing primers being TetR-F and TetR-R.
[0093] The electrophoresis results showed that after continuous passage of the correctly identified positive clone cell line 06, a target fragment of about 730 bp in length could be PCR-generated within 10 generations ( Figure 5 The sequencing results also showed that the cell line matched the original sequence. These results showed that the cell line was continuously passaged for 10 times and the target gene sequence remained stable. The cell line was deposited in Guangdong Microbiological Culture Collection Center with the deposit number GDMCC No: 63272.
[0094] The technical solution of the present disclosure is not limited to the above-mentioned specific embodiments, and all technical variations made according to the technical solution of the present disclosure fall within the protection scope of the present disclosure.
Claims
1. A construction system for expressing a tetracycline repressor protein, the construction system comprising a nucleotide sequence encoding the tetracycline repressor protein.
2. The construction system according to claim 1, characterized in that: The nucleotide sequence encoding the tetracycline repressor protein is as shown in SEQ ID NO: 1 or has one or more nucleotide substitutions, deletions or insertions compared to the nucleotide sequence shown in SEQ ID NO: 1; and / or The nucleotide sequence encoding the tetracycline repressor protein is inserted into a cloning vector to obtain a tetracycline repressor protein expression vector; Preferably, the cloning vector is selected from at least one of pMD18T, pUC18, pMD19T, pbs-sk or pGEM-T.
3. The construction system according to claim 1, characterized in that: The construction system also includes a site-directed cutting sequence, Preferably, the site-directed cleavage sequence is as shown in SEQ ID NO: 2, or has one or more nucleotide substitutions, deletions or insertions compared to the sequence shown in SEQ ID NO: 2; Preferably, the site-directed cleavage sequence is inserted into a donor plasmid. More preferably, the donor plasmid is selected from pLentiCRISPRv2.
4. A cell line obtained using the construction system according to any one of claims 1 to 3.
5. The cell line according to claim 4, characterized in that The cell line is a human cell; preferably, the human cell is a HEK293 cell.
6. The cell line according to claim 4, characterized in that The cell line is a tetracycline repressor protein stably expressing cell line, which was deposited in Guangdong Provincial Microbiological Culture Collection Center on March 13, 2023, with the deposit number GDMCC No: 63272.
7. A method for constructing a cell line stably expressing tetracycline repressor protein, characterized in that: The method comprises co-transfecting the tetracycline repressor protein expression vector and the donor plasmid in the construction system of any one of claims 1 to 3 into cells.
8. The method according to claim 7, characterized in that The cells are human cells, preferably HEK293 cells; Preferably, cells are selected for resistance to bleomycin.
9. The method according to claim 7 or 8, characterized in that: The method comprises the following steps: (1) co-transfecting the linearized product of the tetracycline repressor protein expression vector and the donor plasmid into cells; (2) using bleomycin to screen the cells obtained in step (1) for resistance, preferably, the concentration of bleomycin is preferably 200-500 μg / ml; (3) Obtain a cell line stably expressing tetracycline repressor protein through monoclonal screening.
10. Use of the construction system according to any one of claims 1 to 3, the cell line according to any one of claims 4 to 6, or the cell line constructed by the method according to any one of claims 7 to 9 in gene function research, research and production of preventive and therapeutic biological products.
